ENDPOINTS

Bristol Myers prunes pipeline amid new round of cost cuts

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials. The pipeline cuts disclosed Thursday follow news of a

Feb 9, 2025 - 21:50
 0
Bristol Myers prunes pipeline amid new round of cost cuts
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials. The pipeline cuts disclosed Thursday follow news of a
Read More

Tags:

Previous Article

Acelyrin and Alumis to merge in deal combining cash, assets

Next Article

Pfizer hires Novartis oncology exec to steer its cancer ambitions

Related Posts

Trump’s tariff impact likely ‘minimal’ for brand-name drugmakers  

Trump’s tariff impact likely ‘minimal’ for brand-name d...

Feb 10, 2025  0

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

AstraZeneca takes $753M charge on abandoned complement ...

Feb 9, 2025  0

Sionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for its own listing

Sionna inks $191M IPO for cystic fibrosis pipeline as A...

Feb 9, 2025  0